Botox 100 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMEA2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,569
Award facts
- Contract value 100% obligated
- $49,569.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $49.6K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botox 100 Unit vials. This firm fixed-price delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, represents a direct execution under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency. The award includes no set-aside designation, indicating the vendor competed in open procurement. DMS Pharmaceutical Group maintains substantial federal contracting experience as a critical supplier within the Department of Defense pharmaceutical supply chain, with SAM registration dating to July 2001.
This delivery order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion Defense Logistics Agency acquisition strategy designed to streamline pharmaceutical procurement for military healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under this program valued at $499.999 billion with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's product portfolio encompasses branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, positioning it as a key regional prime vendor supporting recurring pharmaceutical supply needs across Department of Defense healthcare operations globally. No subcontractors are identified in this award.
Quick answers
Who was awarded contract SPE2DR26FMEA2?
SPE2DR26FMEA2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FMEA2 worth?
The government has obligated $49,569 on SPE2DR26FMEA2.
Is contract SPE2DR26FMEA2 an order under another contract?
Yes. SPE2DR26FMEA2 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEA2 competed?
The extent of competition for SPE2DR26FMEA2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award